Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

United Health Products, Inc. (UEEC)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.7700-0.0100 (-1.28%)
At close: 3:41PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.7800
Open0.7500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.7500 - 0.7800
52 Week Range0.6800 - 1.3000
Volume81,006
Avg. Volume89,931
Market Cap174.249M
Beta (5Y Monthly)-0.60
PE Ratio (TTM)N/A
EPS (TTM)-0.2170
Earnings DateJun 29, 2020 - Jun 30, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    United Health Products Provides Business Update

    HENDERSON, Nev., Oct. 07, 2021 (GLOBE NEWSWIRE) -- United Health Products, Inc. (OTCPK: UEEC), (UHP), developer, manufacturer and marketer of HemoStyp™, a patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent, today provided an update on its regulatory approval application process and other business activities. As part of its substantive review process to evaluate UHP's PMA (Pre-market Approval) application, the FDA has requested details on certain elements of the HemoStyp

  • Yahoo Finance Video

    Influencers with Andy Serwer: Dan Amos

    In this episode of Influencers, Andy is joined by Aflac Chairman & CEO, Dan Amos, as they discuss Aflac’s record on diversity and inclusion, how the pandemic has affected the insurance business, and the origin story of the famed Aflac duck.

  • ACCESSWIRE

    United Health Products Provides Corporate Update and Announces Equity Financing

    HENDERSON, NV / ACCESSWIRE / June 28, 2021 / United Health Products, Inc. (OTCPK:UEEC), ('UHP'), developer, manufacturer and marketer of HemoStyp, a patented Neutralized Oxidized Regenerated Cellulose hemostatic agent, today provided a corporate update on its current product development and commercialization activities.

Advertisement
Advertisement